Literature DB >> 22693293

Unusual complications of arterial closure devices: a word of warning.

Duncan C Watt1, Ahmed N Assar, Felicity J Meyer.   

Abstract

The authors describe two patients who underwent transfemoral endovascular procedures followed by the use of the Angio-seal arterial percutaneous closure device. In the first patient, distal migration of the device occurred with consequent occlusion of the ipsilateral popliteal artery 2 days post procedure. In the second patient, thrombotic occlusion of the femoral artery occurred and the patient presented with acute leg ischaemia 3 weeks post procedure. Surgical removal of the closure device with consequent revascularisation of the affected leg was achieved in both patients. This report aims to alert clinicians to the possibility of device-induced arterial occlusion, dislodgment and their sequelae.

Entities:  

Mesh:

Year:  2011        PMID: 22693293      PMCID: PMC3132625          DOI: 10.1136/bcr.03.2011.4006

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices.

Authors:  Nipun Arora; Michael E Matheny; Carrie Sepke; Frederic S Resnic
Journal:  Am Heart J       Date:  2007-04       Impact factor: 4.749

Review 2.  Arterial closure devices. A review.

Authors:  J B Madigan; L A Ratnam; A M Belli
Journal:  J Cardiovasc Surg (Torino)       Date:  2007-10       Impact factor: 1.888

3.  Angiographic access site complications in the era of arterial closure devices.

Authors:  Shari L Meyerson; Ted Feldman; Tina R Desai; Jeffrey Leef; Lewis B Schwartz; James F McKinsey
Journal:  Vasc Endovascular Surg       Date:  2002 Mar-Apr       Impact factor: 1.089

Review 4.  Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis.

Authors:  Maria Koreny; Eva Riedmüller; Mariam Nikfardjam; Peter Siostrzonek; Marcus Müllner
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.